Bibliography
- Velagaleti RS , PencinaMJ, MurabitoJMet al. : Long-term trends in the incidence of heart failure after myocardial infarction.Circulation118, 2057–2062 (2008).
- Jessup M , AbrahamWT, CaseyDEet al. : 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.Circulation119, 1977–2016 (2009).
- deFilippi CR , SeligerSL: Biomarkers for prognostication after acute coronary syndromes: new times and statistics.J. Am. Coll. Cardiol.54, 365–367 (2009).
- Kalantar-Zadeh K , BlockG, HorwichT, FonarowGC: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure.J. Am. Coll. Cardiol.43, 1439–1444 (2004).
- Tang WH , FrancisGS, MorrowDAet al. : National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure.Circulation116, E99–E109 (2007).
- Heart Failure Society of America: Evaluation of patients for ventricular dysfunction and heart failure. J. Card. Fail.12, E16–E25 (2006).
- Maisel AS , KrishnaswamyP, NowakRMet al. : Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N. Engl. J. Med.347, 161–167 (2002).
- Januzzi JL Jr, Camargo CA, Anwaruddin S et al.: The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am. J. Cardiol.95, 948–954 (2005).
- Fonarow GC , PeacockWF, PhillipsCO, GivertzMM, LopatinM: Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.J. Am. Coll. Cardiol.49, 1943–1950 (2007).
- Januzzi JL Jr, Sakhuja R, O‘Donoghue M et al.: Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med.166, 315–320 (2006).
- Moe GW , HowlettJ, JanuzziJL, ZowallH: N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study.Circulation115, 3103–3110 (2007).
- Mueller C , ScholerA, Laule-KilianKet al. : Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.N. Engl. J. Med.350, 647–654 (2004).
- Singer AJ , BirkhahnRH, GussDet al. : Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial BNP testing on patient management.Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.108.826685 (2009) (Epub ahead of print).
- Schneider HG , LamL, LokugeAet al. : B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial.Ann. Intern. Med.150, 365–371 (2009).
- O‘Neill JO , Bott-SilvermanCE, McRaeAT 3rd et al.: B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am. Heart J.149, 363–369 (2005).
- Shah MR , HasselbladV, TasissaGet al. : Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial).Am. J. Cardiol.100, 1427–1433 (2007).
- Mehra MR , UberPA, ParkMHet al. : Obesity and suppressed B-type natriuretic peptide levels in heart failure.J. Am. Coll. Cardiol.43, 1590–1595 (2004).
- Taylor JA , ChristensonRH, RaoK, JorgeM, GottliebSS: B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures.Am. Heart J.152, 1071–1076 (2006).
- Troughton RW , PriorDL, PereiraJJet al. : Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function.J. Am. Coll. Cardiol.43, 416–422 (2004).
- Tang WH , GirodJP, LeeMJet al. : Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure.Circulation108, 2964–2966 (2003).
- James KB , TroughtonRW, FeldschuhJ, SoltisD, ThomasD, Fouad-TaraziF: Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study.Am. Heart J.150, 984 (2005).
- van Kimmenade RR , JanuzziJL Jr, Bakker JA et al.: Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J. Am. Coll. Cardiol.53, 884–890 (2009).
- Hogenhuis J , VoorsAA, JaarsmaT, HillegeHL, BoomsmaF, van Veldhuisen DJ: Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur. J. Heart Fail.7, 81–86 (2005).
- Pfisterer M , BuserP, RickliHet al. : BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.JAMA301, 383–392 (2009).
- Jourdain P , JondeauG, FunckFet al. : Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study.J. Am. Coll. Cardiol.49, 1733–1739 (2007).
- Peacock WF t, De Marco T, Fonarow GC et al.: Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med.358, 2117–2126 (2008).
- Cardinale D , SandriMT, ColomboAet al. : Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.Circulation109, 2749–2754 (2004).
- Cardinale D , ColomboA, SandriMTet al. : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.Circulation114, 2474–2481 (2006).
- Fonarow GC , AdamsKF Jr, Abraham WT, Yancy CW, Boscardin WJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA293, 572–580 (2005).
- Filippatos G , RossiJ, Lloyd-JonesDMet al. : Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.J. Card. Fail.13, 360–364 (2007).
- Forman DE , ButlerJ, WangYet al. : Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J. Am. Coll. Cardiol.43, 61–67 (2004).
- Gottlieb SS , AbrahamW, ButlerJet al. : The prognostic importance of different definitions of worsening renal function in congestive heart failure.J. Card. Fail.8, 136–141 (2002).
- Pilz S , MarzW, WellnitzBet al. : Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography.J. Clin. Endocrinol. Metab.93, 3927–3935 (2008).
- Gheorghiade M , RossiJS, CottsWet al. : Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial.Arch. Intern. Med.167, 1998–2005 (2007).
- Packer M , LeeWH, KesslerPD, MedinaN, YushakM, GottliebSS: Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure.J. Am. Coll. Cardiol.10, 837–844 (1987).
- Rossi J , BayramM, UdelsonJEet al. : Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.Acute Card. Care9, 82–86 (2007).
- Konstam MA , GheorghiadeM, BurnettJC Jr et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA297, 1319–1331 (2007).
- Paterna S , Di Pasquale P, Parrinello G et al.: Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J. Am. Coll. Cardiol.45, 1997–2003 (2005).
- Anand IS , FloreaVG: High output cardiac failure.Curr. Treat. Options Cardiovasc. Med.3, 151–159 (2001).
- Tang WH : Anemia in heart failure: current evidence and challenges.Rev. Cardiovasc. Med.8, 78–86 (2007).
- Tang WH , TongW, JainA, FrancisGS, HarrisCM, YoungJB: Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.J. Am. Coll. Cardiol.51, 569–576 (2008).
- Felker GM , AllenLA, PocockSJet al. : Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM program and the Duke databank.J. Am. Coll. Cardiol.50, 40–47 (2007).
- Wood P : The erythrocyte sedimentation rate in diseases of the heart.Q. J. Med.5, 1–19 (1939).
- Petersen JW , FelkerGM: Inflammatory biomarkers in heart failure.Congest. Heart Fail.12, 324–328 (2006).
- Anand IS , LatiniR, FloreaVGet al. : C-reactive protein in heart failure: prognostic value and the effect of valsartan.Circulation112, 1428–1434 (2005).
- Tang WH , ShresthaK, Van Lente F et al.: Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am. J. Cardiol.101, 370–373 (2008).
- Tang WH , BrennanML, PhilipKet al. : Plasma myeloperoxidase levels in patients with chronic heart failure.Am. J. Cardiol.98, 796–799 (2006).
- Tang WH , TongW, TroughtonRWet al. : Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.J. Am. Coll. Cardiol.49, 2364–2370 (2007).
- Mocatta TJ , PilbrowAP, CameronVAet al. : Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.J. Am. Coll. Cardiol.49, 1993–2000 (2007).
- Tang WH , TongW, TroughtonRWet al. : Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.J. Am. Coll. Cardiol.49, 2364–2370 (2007).
- Kardys I , KnetschAM, BleuminkGSet al. : C-reactive protein and risk of heart failure. The Rotterdam Study.Am. Heart J.152, 514–520 (2006).
- Ng LL , PathikB, LokeIW, SquireIB, DaviesJE: Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.Am. Heart J.152, 94–101 (2006).
- Tang WH , KatzR, BrennanMLet al. : Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure.Am. J. Cardiol.103, 1269–1274 (2009).
- Vasan RS , SullivanLM, RoubenoffRet al. : Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.Circulation107, 1486–1491 (2003).
- Leyva F , AnkerSD, GodslandIFet al. : Uric acid in chronic heart failure: a marker of chronic inflammation.Eur. Heart J.19, 1814–1822 (1998).
- Anker SD , DoehnerW, RauchhausMet al. : Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.Circulation107, 1991–1997 (2003).
- Hare JM , MangalB, BrownJet al. : Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.J. Am. Coll. Cardiol.51, 2301–2309 (2008).
- Crispell KA , HansonEL, CoatesK, ToyW, HershbergerRE: Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy.J. Am. Coll. Cardiol.39, 1503–1507 (2002).
- Tang WH : Natriuretic peptide measurements in managing heart failure: in theory and in practice.Circ. Heart Fail.2, 380–381 (2009).
- Boisot S , BeedeJ, IsaksonSet al. : Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.J. Card. Fail.14, 732–738 (2008).
- Januzzi JL Jr, Peacock WF, Maisel AS et al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol.50, 607–613 (2007).
- Rehman SU , MuellerT, JanuzziJL Jr: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol.52, 1458–1465 (2008).
- Milting H , EllinghausP, SeewaldMet al. : Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.J. Heart Lung Transplant.27, 589–596 (2008).
- van Kimmenade RR , JanuzziJL Jr, Ellinor PT et al.: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol.48, 1217–1224 (2006).
- Radauceanu A , DuckiC, VirionJMet al. : Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure.J. Card. Fail.14, 467–474 (2008).
- Kempf T , von Haehling S, Peter T et al.: Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol.50, 1054–1060 (2007).
- Dieplinger B , GegenhuberA, HaltmayerM, MuellerT: Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in shortness-of-breath patients.Heart doi: 10.1136/hrt.2009.170696 (2009) (Epub ahead of print).
- Voors AA , von Haehling S, Anker SD et al.: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur. Heart J.30, 1187–1194 (2009).
- Tang WH , WangZ, ChoL, BrennanDM, HazenSL: Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.J. Am. Coll. Cardiol.53, 2061–2067 (2009).
- Tang WH , TongW, ShresthaKet al. : Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure.Eur. Heart J.29, 2506–2513 (2008).
- Wei YJ , HuangYX, ZhangXLet al. : Apolipoprotein D as a novel marker in human end-stage heart failure: a preliminary study.Biomarkers13, 535–548 (2008).
- Wedel H , McMurrayJJ, LindbergMet al. : Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide.Eur. J. Heart Fail.11, 281–291 (2009).
- Hershberger RE , LindenfeldJ, MestroniL, SeidmanCE, TaylorMR, TowbinJA: Genetic evaluation of cardiomyopathy – a Heart Failure Society of America practice guideline.J. Card. Fail.15, 83–97 (2009).
- Liggett SB , Mialet-PerezJ, Thaneemit-ChenSet al. : A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure.Proc. Natl Acad. Sci. USA103, 11288–11293 (2006).
- Taylor MR , SlavovD, HumphreyKet al. : Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.Pharmacogenet. Genomics19, 35–43 (2009).
- McNamara DM , HolubkovR, PostavaLet al. : Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.J. Am. Coll. Cardiol.44, 2019–2026 (2004).
- McKie PM , RodehefferRJ, CataliottiAet al. : Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.Hypertension47, 874–880 (2006).